The US Food and Drug Administration on Friday said it has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.
Developed by USA-based rare seizure specialist Marinus Pharmaceuticals (Nasdaq: MRNS), this is the first treatment for seizures associated with CDD and the first treatment specifically for CDD. The news saw Marinus’ shares rocket almost 50% to $11.54.
The company said Ztalmy is expected to be commercially available in the USA in July following scheduling by the US Drug Enforcement Administration. Ztalmy has been priced at $2,425 per bottle, or $133,000 per year. With discounts, it will cost $105,000 per patient for a year’s treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze